- A + HIGH CONTRAST TURN ON TEXT TO SPEECH HOME ABOUT US PIPELINE TECHNOLOGY INVESTORS NEWS&MEDIA CONTACT & ACCESS Gene Therapy Against Blindness We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies. Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Press Releases 08 September 2016 GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy Paris, France, September 8, 2016 – GenSight Biologics (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that regulatory agencies and ethics committees in the United States, France and the United Kingdom, have authorized a protocol amendment to include teenage patients (15-18 years) in RESCUE and REVERSE, two ongoing Phase III clinical trials of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy (LHON). READ THE FULL PRESS RELEASE 01 September 2016 The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa. The EMA also granted Advanced Therapy Medicinal Product (ATMP) classification to GS030. 11 August 2016 GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option. 13 July 2016 GenSight Biologics announces successful IPO on Euronext Paris. READ ALL PRESS RELEASES Main events 05 - 07 Oct. 2016 Cell&Gene Meeting on the mesa, La Jolla (CA), USA GenSight will participate to the 11th Annual Scientific Program and 6th Annual Partnering Forum organized by ARM and give a presentation on Day 1 at 3:00pm. 05 - 08 Oct. 2016 European Association for Vision and Eye Research, EVER, Nice, France GenSight will give an oral presentation on : "Relationship between immune response and ocular inflammation after intravitreal injection of rAAV2/2–ND4 (GS010) in Leber Hereditary Optic Neuropathy (LHON) patients" on Wednesday 25 October in session Neuro-ophthalmology and paediatric ophthalmology. 18 - 21 Oct. 2016 European Society of Gene and Cell Therapy (ESGCT), Florence, Italy GenSight will give an oral presentation on "One-year follow-up study results after intravitreal GS010 injection in patients with vision loss due to LHON", Wednesday 19 October. A Poster on the relationship between ocular inflammation and immune responses following IVT injection of GS010 will also be presented. 03 - 04 Nov. 2016 2nd Annual Cell & Gene Therapy Congress, London, UK GenSight will give an oral presentation on Day 1 on : “Translational development of GS030, an optogenetic therapy for retinal dystrophies combining a stimulating medical device.” OTHER EVENTS Discover our corporate video FRENCH (5'23") ENGLISH (5'23") HOME ABOUT US Company Scientific Founders Management Board Scientific advisory board Partners PIPELINE Leber Hereditary Optic Neuropathy (LHON) Retinitis Pigmentosa (RP) Geographic Atrophy in Dry-AMD Clinical trials TECHNOLOGY Gene Therapy Mitochondrial Targeting Sequence (MTS) Optogenetics INVESTORS Welcome ! Stock data Press releases News room Documentation Contact NEWS&MEDIA Press releases Events CONTACT & ACCESS ©2015-2016 Gensight Biologics Terms of Use Sitemap Gensight Biologics 74, rue du Faubourg Saint-Antoine 75012 Paris, FRANCE Phone: +33 1 76 21 72 20 infos@gensight-biologics.com